Rio de Janeiro, May 9, 2013 - Amil Participações S.A. ("Company") hereby makes known to its shareholders and to the market that received today, May 9, 2013, the OFÍCIO/CVM/SEP/GEA-2/Nº 127/2013, informing that the Brazilian Securities granted, on this date, the deregistration for the trading mentioned in the Article 21 of the Law No. 6.385/1976, until now held on behalf of the Company.

To access the .pdf version, click here.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

Launching of the Unified Tender Offer for Acquisition of Shares

Rio de Janeiro, March 21, 2013 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, hereby informs its shareholders and the market that, in connection with the indirect acquisition of control of the Company on October 5, 2012, and in addition to the material facts disclosed on October 8 and 30, 2012 and on November 23 and 28, 2012, Mind Solutions S.A. ("Offeror"), current direct controlling shareholder of the Company and an affiliate of UnitedHealth Group Incorporated, published on this date the notice (Edital de Oferta Pública) of the unified public tender offer for the acquisition of up to the totality of the ordinary shares of the Company not held by the Offeror ("Notice" and "Offer", respectively). According to the Notice, the term for acceptance of the Offer by the Company‘s shareholders commences on this date.

The Notice is available in the following websites: www.cvm.gov.br, www.bmfbovespa.com.br and www.amilpar.com.br/ir.

To access the full version of the Notice to the Market, click here.

To access the Notice of Unified Tender Offer for the Acquisition of Shares, click here.

To access the Statement Form, click here.

To access the Price Justification Statement, click here.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

Rio de Janeiro, October 30, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, informs that, on October 29, 2012, was applied to CVM request for the registration of a public tender offer for the acquisition of the Company‘s shares.

To access the Relevant Fact, click here.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

Rio de Janeiro, October 26, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, informs that the control transference to UnitedHealth Group was concluded.

To access the Relevant Fact, click here.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

Rio de Janeiro, October 23, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil informs its shareholders and the market that on October 22, 2012, the Brazilian Healthcare Regulatory Agency - ANS ("ANS") approved the association between the Company and UnitedHealth Group Incorporated ("Association"), in the terms and conditions of the contract signed on the evening of October 5, 2012 ("Contract") by Company’s direct and indirect controlling shareholders. It is important to mention that the effectiveness of the Association is subject to other conditions to be accomplished according to the Contract.

The Company will keep the market informed about upcoming events of the aforementioned Deal.

To access the .pdf version, click here.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

Rio de Janeiro, October 8, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil and UnitedHealth Group (NYSE: UNH) announced their association today, bringing together two leading organizations with the broad scale, distinctive resources and advanced technology to help modernize the performance of the health systems and serve the health care needs of consumers in their markets in the Americas.

To access the .pdf full version of the Press Release, click here.

Next Events: Conference Calls

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Webcast:
The Conference Call audio will be live broadcasted on the Internet at the following link: http://webcast.mzvaluemonitor.com/Home/Login/520

Replay:
A conference call replay facility will be available from October 8 through October 14. To access the replay, dial the above mentioned numbers or access our website.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

Condition accomplished for the acquisition of Santa Lúcia Hospital

Rio de Janeiro, September 25, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, in accordance with CVM Instruction 358, of January 3, 2002, informs that the suspensive condition for the acquisition of Santa Lúcia Hospital was completely accomplished, with the sale of Amilpar’s indirect controlling shareholder stake in Medise - Medicina Diagnóstico e Serviços S.A. This operation aims to follow the decision of the Brazilian antitrust regulator - CADE, of August 29, 2012.

To access the .pdf version of the Press Release, click here.

Rio de Janeiro, August 7, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, announces today its consolidated results for June 30, 2012.

To access the .pdf version of the Earnings Release 2Q12, click here.

Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, announces its Results Disclosure Schedule for the second quarter of 2012.

Earnings Release
Tuesday, August 7, 2012 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: http://webcast.mzvaluemonitor.com/Home/Login/611c82ab-4006-409b-8dba-32585c74fd0c

Replay:
A conference call replay facility will be available from August 8 through August 14. To access the replay, dial the above mentioned numbers or access our website.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

To download the Invitation, click here.

Rio de Janeiro, July 16, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare company in Brazil, informs that its National Long-Term Rating was upgrade by Fitch from "AA-(bra)", to "AA (bra)", with stable outlook.

The improvement in Amilpar‘s Rating reflected the consistency of results and the solidity of the group.

To access the .pdf version of the Press Release, click here.

Rio de Janeiro, May 8, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, announces today its consolidated results for March 31, 2012.

To access the .pdf version of the Earnings Release 1Q12, click here.

Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, announces its Results Disclosure Schedule for the first quarter of 2012.

Earnings Release
Tuesday, May 8, 2012 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: http://webcast.mz-ir.com/publico.aspx?codplataforma=3777

Replay:
A conference call replay facility will be available from May 9 through May 15. To access the replay, dial the above mentioned numbers or access our website.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

To download the Invitation, click here.

Change of Independent Auditor

Rio de Janeiro, March 29, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, announces that in accordance with Article 31 of CVM Instruction 308/99, which determines the change of independent auditors every five years, was contracted, on March 22, 2012, Grant Thornton Auditores Independentes to perform the auditing of the Company’s financial statements for the year ended December 31, 2012, including the review of the quarterly information since the first quarter of 2012, replacing Ernst & Young Terco Auditores Independentes.

We also inform that the Company obtained the consent of Ernst & Young Terco Auditores Independentes, Amilpar’s former independent auditor, on the above-mentioned change.

To access the .pdf version of the Press Release, click here.

Payment of Short-Term Debenture

Rio de Janeiro, March 19, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, announces that it was paid, on this date, the 2^nd issuance of debentures, from March 2010, at the amount of R$ 158.9 million, out of which R$ 150 million related to principal and R$ 8.9 million to interest.

This settlement is aligned with the Company’s strategy of debt profile extension. To make this payment, were used proceeds from the 4^th issuance of debentures, occurred at the end of 2011.

To access the .pdf version of the Press Release, click here.

New distribution channel for Affinity Plans

Rio de Janeiro, March 12, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, in accordance with CVM Instruction 358, of January 3, 2002, informs that was celebrated a commercial agreement with Qualicorp S.A., which permits the company to distribute health plans in the Affinity segment (medical and dental plans), offered by Amilpar.

With this new commercial agreement, Amilpar increases even more its presence in the distribution channel of Affinity segment, while Qualicorp increase its range of products, including Affinity plans from the largest healthcare company in the country.

To access the .pdf version of the Press Release, click here.

Distribution of Dividends

Rio de Janeiro, March 12, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, informs its Shareholders that the Board of Directors of the Company, in a meeting held today, approved the payment of Dividends at the amount of R$ 0.1396 per common share, corresponding to the total amount of R$ 50 million. The payment will be made on April 26, 2012, based on shareholders’ position of March 13, 2012.

Please note that shares acquired on March 14, 2012 and thereafter, will be traded EX-DIVIDENDS.

To access the .pdf version of the Notice to Shareholders, click here.

Rio de Janeiro, March 12, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3.SA), the largest healthcare operator in Brazil, announces today its consolidated results for December 31, 2011, in accordance with Brazilian corporate law and the ANS account chart. Since December 2010, Amilpar’s consolidated financial statements have included the new accounting rules aligning Brazilian corporate law with International Financial Reporting Standards (IFRS). As a result, the figures of previous periods may present variations in relation to the figures already published.

To access the .pdf version of the Earnings Release 4Q11, click here.

Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, announces its Results Disclosure Schedule for the fourth quarter of 2011.

Earnings Release
Monday, March 12, 2012 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: http://webcast.mz-ir.com/publico.aspx?codplataforma=3572

Replay:
A conference call replay facility will be available from March 13 through March 19. To access the replay, dial the above mentioned numbers or access our website.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

To download the Invitation, click here.

New Amil Dental Website

Rio de Janeiro, February 13, 2012 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, informs that was launched a new website for its Dental products line, available (only in Portuguese) at www.amildental.com.br.

The new website will be the major communication channel between dental customers, contracted network and brokers of all Amil, Medial and Dix lines. The website offers a wide range of services, making the access to business information easier for users, with information such as new Dental line products and contracted network consulting. Moreover, from now on it is also available the tool "Indique seu Dentista (Indicate your Dentist)", whereby users can indicate a professional to join the contracted network of Amil Dental.

The new website is one more project of Amil Dental to increase brand visibility and also to make the processes more modern and agile.

Currently Amil Dental is the second largest dental plans operator in Brazil, registering an increase of 32% in its membership in the last 12 months ended September 30, 2011. Despite representing a small percentage of Amilpar’s total revenues, dental plans are highly attractive given the superior margin and cash generation of the segment.

To access the .pdf version of the Press Release, click here.

Rio de Janeiro, December 5, 2011 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, is pleased to invite you to its Public Meeting with Investors and Analysts.

Public Meeting with Investors and Analysts
Thursday, December 15, 2011
Time: 10:00 a.m. (Brasília Time)
Place: Amilpar Headquarters - Centro Empresarial Barra Shopping
Av. das Américas, 4.200 - Bloco 3 - Rio de Janeiro - RJ

RSVP: Click here or call +55 (11) 3529-3553

Please confirm your presence until December 12^th.

The presentation will be made in portuguese.

To acess the PDF version of the invitation, click here.

Rio de Janeiro, November 9, 2011 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, in accordance with article 157, paragraph 4 of Law 6,404/76 (Brazilian Corporate Law), as amended, and CVM Instruction 358/02, as amended, informs its shareholders and the market, that its Board of Directors approved today the 4th Issuance of Common Debentures, Unsecured not convertible into shares, Single Series, for public distribution, with restricted selling efforts, according to CVM Instruction 476/09, of January 16, 2009, as amended, in order to extend short term debt and to strengthen the net cash of the Company.

The main characteristics of this Issuance are described bellow:

- Amount: R$ 300 million
- Term: 3 years
- Remuneration: up to 110% of CDI, to be confirmed after Bookbuilding process
- Payment of the remuneration: Every six months
- Amortization: in one installment, on the Maturity Date
- Coordinators: BTG Pactual and HSBC

To access the complete version of the Relevant Fact, click here.

Rio de Janeiro, November 08, 2011: Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3.SA), the largest healthcare operator in Brazil, announces today its consolidated results for September 30, 2011, in accordance with Brazilian corporate law and the ANS account chart. Since December 2010, Amilpar’s consolidated financial statements have included the new accounting rules aligning Brazilian corporate law with International Financial Reporting Standards (IFRS). As a result, the figures of previous periods may present variations in relation to the previously published figures.

To access the .pdf version of the Earnings Release 3Q11, click here.

Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, announces its Results Disclosure Schedule for the third quarter of 2011.

Earnings Release
Tuesday, November 08, 2011 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Webcast:
O Áudio das teleconferências e a apresentação de slides serão disponibilizados através do seguinte link: http://webcast.mz-ir.com/publico.aspx?codplataforma=3264

Replay:
A conference call replay facility will be available from November 09 through November 15. To access the replay, dial the above mentioned numbers or access our website.

Investor Relations
Phone.: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Site: www.amilpar.com.br/ir

To download the Invitation, click here.

Rio de Janeiro, August 09, 2011: Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3.SA), the largest healthcare operator in Brazil, announces today its consolidated results for June 30, 2011, in accordance with Brazilian corporate law and the ANS account chart. Since 2010, Amilpar’s consolidated financial statements have included the new accounting rules aligning Brazilian corporate law with international financial reporting standards (IFRS). As a result, the figures of previous periods may present variations in relation to the previously published.

To access the .pdf version of the Earnings Release 2Q11, click here.

Amil Participações S.A. (BM&FBovespa: AMIL3), the largest healthcare operator in Brazil, announces its Results Disclosure Schedule for the second quarter of 2011.

Earnings Release
Tuesday, August 09, 2011 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Investor Relations:
Phone: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Website: www.amilpar.com.br/ir

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: http://webcast.mz-ir.com/publico.aspx?codplataforma=2960

Replay:
A conference call replay facility will be available from August 10 through August 16. To access the replay, dial the above mentioned numbers or access our website.

To download the Invitation, click here

Acquisition of Lincx

Rio de Janeiro, May 25, 2011: AMIL PARTICIPAÇÕES S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL 3.SA), the largest healthcare operator in Brazil, in accordance with CVM Instruction 358, of January 3, 2002, informs that signed today through its subsidiary Amil Assistência Médica Internacional S.A. (“Amil”), a Purchase Agreement with the controlling shareholders of Lincx Sistemas de Saúde Ltda. (“Lincx”) for the acquisition and transference of up to 100% of their interest in that company.

The amount to be paid for the acquisition, subject to confirmation after the auditing process, is R$ 170 million and should be made in 4 installments. The first, in the amount of R$ 60 million, should be paid at moment of the closure of the deal, the 2^nd installment, in the amount of R$ 25 million, 90 days after the 1^st installment, the 3^rd, in the amount of R$ 60 million, 90 days after the 2^nd installment and the 4^th and last installment, in the amount of R$ 25 million, 180 days after the 3^rd installment. These values will be adjusted for 105% of the CDI variation (average interbank deposit rate in Brazil), since the contract signature until the effective payment. Lincx has approximately R$ 20 million in cash, which will be part of the assets acquired - reducing the Equity Value to roughly R$ 150 million - and has no financial debt.

Lincx annualized revenues in 2011 are close to R$ 220 million with an EBITDA margin of approximately 8% (without synergies). The company has a portfolio with 36,000 members, 30,000 of which in health plans (being approximately 76% of corporate clients) and 6,000 in dental plans, operates mainly in the state of São Paulo, with branches in Londrina (state of Paraná) and Rio de Janeiro, in the Premium segment - focused in high income clients - for 18 years.

Before this acquisition, Amilpar already served the high income segment through its own brand AMIL ONE, launched in 2010, and now our presence in this market will increase significantly. It is important to highlight that all contracts previously undertaken by Lincx will be respected and that, from now on, all Lincx’s stakeholders, specially doctors and beneficiaries, will count with even more solidity for being with the largest private healthcare company in Brazil. This deal reinforces Amilpar’s strategy of combining organic growth with strategic acquisitions.

The effectiveness of this acquisition is subject to the approval of the Brazilian Healthcare Agency - ANS (“Suspensive Condition”). This deal will also be submitted to the analysis of the Brazilian System of Competition Defense (CADE).

To access the .pdf version of the Press Release, click here.

Rio de Janeiro, May 10, 2011: Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3.SA), the largest healthcare operator in Brazil, announces today its consolidated results for March 31, 2011, in accordance with Brazilian corporate law and the ANS account chart. Since 2010, Amilpar’s consolidated financial statements include the new accounting rules aligning Brazilian corporate law with international financial reporting standards (IFRS).

To access the .pdf version of the Earnings Release 1Q11, click here

Amil Participações S.A. (BM&FBovespa: AMIL3), the largest healthcare operator in Brazil, announces its Results Disclosure Schedule for the first quarter of 2011.

1Q11 Earnings Release
Tuesday, May 10, 2011 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Investor Relations:
Phone: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Website: www.amilpar.com.br/ir

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: http://webcast.mz-ir.com/publico.aspx?codplataforma=2735

Replay:
A conference call replay facility will be available from May 11 through May 17. To access the replay, dial the above mentioned numbers or access our website.

To download the Invitation, click here

Acquisition of Hospital Pasteur

Rio de Janeiro, April 28, 2011: AMIL PARTICIPAÇÕES S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL 3.SA), the largest healthcare company in Brazil, in accordance with CVM Instruction 358, of January 3, 2002, informs that signed today through its subsidiary Esho - Empresa de Serviços Hospitalares S.A. an agreement with the owners of Méier Medical Center Ltda., also known as Hospital Pasteur (“Pasteur”) for the acquisition and transference of the totality of the representative quotas of Pasteur’s capital. Our indirect controlling shareholder is one of Pasteur’s owners, with an interest of 60.85%. Amilpar represents approximately 50% of the revenues presented by Pasteur in 2010.

The total amount of the deal is R$ 90 million, R$ 43 million of which for the acquisition of 60.85% from our indirect controlling shareholder’s interest, and R$ 47 million for 39.15% from the remaining shareholders. Considering these values, our indirect controlling shareholder will receive a lower amount compared to that offered for the other shareholders, which corresponds to the investment he made in Pasteur adjusted by the inflation. The payment will be made in 35 monthly and consecutive installments.

The hospital is located in the North region of the city of Rio de Janeiro and has a total capacity of 200 beds in own real estate, which will be included in the acquisition - with 17,000 square meters, and is considered the main hospital reference in its region. It has an average occupancy rate above 90% and annual revenues of approximately R$ 70 million. This acquisition reinforces Amilpar’s investment strategy, consolidating even more its leadership in Rio de Janeiro.

To access the .pdf version of the Press Release, click here.

Distribution of Dividends

Rio de Janeiro, March 22, 2011: AMIL PARTICIPAÇÕES S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL 3.SA), informs its Shareholders that the Board of Directors of the Company, in a meeting held on March 21, 2011, approved the payment of Dividends at the amount of R$ 0.1118 per common share, corresponding to the total amount of R$ 40 million. The payment will be made on May 5, 2011, based on shareholders’ position of March 23, 2011.

Please note that shares acquired on March 24, 2011 and thereafter, will be traded EX-DIVIDENDS.

To access the .pdf version of the Notice to Shareholders, click here.

Rio de Janeiro, March 22, 2011: Amilpar (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare company in Brazil, announced today its consolidated results for December 31, 2010, in accordance with Brazilian corporate law and the ANS account chart. As of this year, Amilpar’s consolidated financial statements include the new accounting rules aligning Brazilian corporate law with international financial reporting standards (IFRS). However, the impact of the new rules on Company’s results was negligible. Additionally, it is also worth noting that the acquisition of Medial Saúde S.A. control occurred on December 1, 2009, consequently, the consolidated results for the fourth quarter and full year of 2009 were impacted by Medial’s results in only one month.

To access the .pdf version of the Earnings Release 4Q10, click here

Amil Participações S.A. (BM&FBovespa: AMIL3), the largest healthcare company in Brazil, announces its December 2010 Earnings Release Schedule:

2010 Earnings Release
March 22, 2011 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Investor Relations:
Phone: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Website: www.amilpar.com.br/ir

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: http://webcast.mz-ir.com/publico.aspx?codplataforma=2558

Replay:
A conference call replay facility will be available from March 23 through March 29. To access the replay, dial the above mentioned numbers or access our website.

To download the Invitation, click here

Outsourcing of laboratory tests in São Paulo

Rio de Janeiro, February 28, 2011: AMIL PARTICIPAÇÕES S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ e APAR ; Reuters: AMIL 3.SA), in accordance with CVM Instruction 358, of January 3, 2002, informs that signed an agreement with Diagnósticos da América S.A. (“DASA”) for the outsourcing of laboratory tests of clinical analysis, currently done by our own diagnostics unit (Foccus/ Total) in São Paulo inside our hospitals and medical centers, with exclusivity for DASA.

The amounts per test to be paid for DASA in this outsourcing will be approximately 10% lower compared to the unit cost currently obtained at our own diagnostics unit, resulting in a reduction of around R$ 7 million per year.

Additionally, Amil will receive a 5% discount on its prices actually charged by DASA‘s services, due to Amilpar’s members usage of DASA’s service units, which represents economies of approximately R$ 7.5 million per year, during 15 years.

Furthermore, based on the contract currently in place for laboratory services, Amilpar maintains its progressive discounts based on volume.

DASA will pay R$ 9.7 million for the exclusivity in conducting clinical analysis tests in the units subject of this agreement, which will be enough to cover all costs related to the closure of this unit (Foccus/ Total), as layoffs and terminations costs.

Therefore, Amilpar will benefit from the reduction in its clinical costs, without the maintenance of an infrastructure limited by the lack of economies of scale.

To download the file, click here.

Right of First Refusal Exercise for the Acquisition
of Hospital Samaritano in Rio de Janeiro

Rio de Janeiro, February 2, 2011: Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ e APAR ; Reuters: AMIL 3.SA), the largest healthcare company in Brazil, in accordance with CVM Instruction 358, of January 3, 2002, informs that in the Board of Directors meeting held yesterday, it was decided that Amilpar, through its indirect subsidiary ESHO - Empresa de Serviços Hospitalares S.A., will exercise the right of first refusal for the acquisition of Hospital Samaritano (Clínica Médico Cirúrgica Botafogo S.A.). The conditions and values are the same described in the Press Release of December 13, 2010. The decision taken by the independent board member was ratified by the other members of the Board of Directors, with abstention of Mr. Edson de Godoy Bueno and Ms. Dulce Pugliese de Godoy Bueno.

To download the file, click here.

Acquisition Of Hospital Samaritano By Indirect Controlling Shareholder

Rio de Janeiro, December 13, 2010: Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ e APAR ; Reuters: AMIL 3.SA), the largest healthcare company in Brazil, in accordance with CVM Instruction 358, of January 3, 2002, informs that the Hospital de Clínicas de Niterói Ltda. (“HCN”), a company owned by our indirect controlling shareholder, signed Agreement aiming the acquisition of up to 100% of the shares representatives of the capital stock of Hospital Samaritano (“Samaritano”) for the total amount of R$ 180 million, to be paid as follows: R$ 47 million at the signing of the final Agreement (after an auditing process), R$ 43 million on July 10, 2011 and the balance in 4 equal, biannual and successive installments, being the first on January 10, 2012. HCN will take over Samaritano’s liabilities and contingencies up to the limit of R$ 5 million. This deal has as suspensive factor the auditing process, to be concluded up to 90 days.

After the aforementioned auditing process and the accomplishment of the suspensive conditions, this acquisition, as well as all the other involving related parties will be subject to Amilpar’s Board of Directors approval (Due to the Price-Arrangement and Right of First Refusal Agreement - Contrato de Assunção de Obrigações e Outras Avenças - signed between Amilpar and its controlling shareholders), in which Amilpar has the option of, through its Board of Directors, decide over the convenience of the exercise of the right of first refusal on the purchase of Samaritano by Amilpar or its subsidiaries.

Samaritano is located at the South region of the city of Rio de Janeiro, has 93 beds and is renowned as the best hospital in this town and one of the best in Brazil. The annual revenue of the hospital is approximately R$ 210 million.

To download the file, click here.

Rio de Janeiro, November 23, 2010: Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ e APAR ; Reuters: AMIL 3.SA), the largest healthcare company in Brazil, in accordance with CVM Instruction 358/02, informs that its controlling shareholders sold 2.9% of common shares of the Company’s capital stock, through an auction at BM&FBOVESPA.

The main objective of this offer was to raise shares’ free float in the market, considering the strong demand occurred in the last few weeks due to the inclusion of the Company in the MSCI Brazil Standard index. Before the offer, the percentage of shares in free float was 27.7% and, since now, will become 30.6%.

After the offer, the controlling shareholders remained with a participation of 66.8% of Amilpar’s total capital, therefore nothing changes in terms of management and long term goals.

To download the file, click here.

Rio de Janeiro, November 10, 2010: Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ e APAR ; Reuters: AMIL 3.SA), the largest healthcare company in Brazil, announced today its consolidated results for the third quarter of 2010 (3Q10), in accordance with Brazilian corporate law and the ANS rules. As of this quarter, we will be presenting consolidated results only (including Medial since 2010) given the current integration phase of the companies.

To download the file, click here.

Amil Participações S.A. (BM&FBovespa: AMIL3), the largest healthcare company in Brazil, announces its Earnings Release Schedule for the third quarter of 2010:

3Q10 Earnings Release
November 10, 2010 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Investor Relations:
Phone: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Website: www.amilpar.com.br/ir

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: www.amilpar.com.br/ir

Replay:
A conference call replay facility will be available from November 11 through November 17. To access the replay, dial the above mentioned numbers or access our website.

To download the file, click here

Rio de Janeiro, September 24, 2010 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ e APAR ; Reuters: AMIL3 SA), the largest healthcare company in Brazil, informs that its Board of Directors approved today the 3rd Issuance of Common Debentures, not convertible into shares, with Floating Guarantee, up to four series, for public distribution, with restricted selling efforts (“Debentures”) from Amilpar (“Restricted Offering” and “Issuance”, respectively), according to CVM Instruction 476/09. Up to 900,000 (nine hundred thousand) Debentures will be issued, with a unit nominal value of R$ 1,000.00 (one thousand reais). The total amount of the issuance will be up to R$ 900,000,000.00 (nine hundred million reais).

The issuance will be made through up to 4 (four) series, in accordance with paragraph 3, article 59 of Brazilian Corporate Law. The Debentures of each series will have the following expiration dates: (a) 1st series: 3 (three) years from its issuance date, expiring on October 15, 2013; (b) 2nd series: 4 (four) years from its issuance date, expiring on October 15, 2014; (c) 3rd series: 5 (five) years from its issuance date, expiring on October 15, 2015; (d) 4th series: 5 (five) years from its issuance date, expiring on October 15, 2015.

The Debentures of the 1st series will have a remuneration which will include interests on its unit nominal value, calculated exponentially and cumulatively, pro rata temporis, since the issuance date or the last payment date of the remuneration of the 1st series until the date of the effective payment, corresponding to the variation of CDI, on its percentage form per year, base of 252 work days, plus an extra interest limited to 1.40% per year, base of 252 work days, to be defined after Bookbuilding process. The Debentures of the 2nd series will have a remuneration which will include interests on its unit nominal value, calculated exponentially and cumulatively, pro rata temporis, since the issuance date or last payment date of the remuneration of the 2nd series until the date of the effective payment, corresponding to the variation of CDI, on its percentage form per year, base of 252 work days, plus an extra interest limited to 1.50% per year, base of 252 work days, to be defined after Bookbuilding process. The Debentures of the 3rd series will have a remuneration which will include interests on its unit nominal value, calculated exponentially and cumulatively, pro rata temporis, since the issuance date or the last payment date of the remuneration of the 3rd series until the date of the effective payment, corresponding to the variation of CDI, on its percentage form per year, base of 252 work days, plus an extra interest limited to 1.60% per year, base of 252 work days, to be defined after Bookbuilding process. The remuneration of the Debentures of 1st, 2nd, and 3rd series will be calculated exponentially and cumulatively, pro rata temporis, by elapsed work days, incident on the unit nominal value or the balance of the nominal value, since the issuance date or the date of payment of the respectively prior remuneration, as appropriate, until the respective expiration date, and paid at the end of each capitalization period.

Since the issuance date, the Debentures of the 4th series will have a remuneration equivalent to maximum interest of 1.50% per year, base of 252 work days, above the indicative rate of the Brazilian Association of Financial and Capital Markets Entities (ANBIMA) for the NTNB 2015 remuneration, to be determined by the arithmetic average of the 3 last days prior to the Bookbuilding process, exponentially and cumulatively pro rata temporis by elapsed work days, incident on its adjusted nominal value not amortized of the Debentures of the 4th series, since the issuance date or the last payment date of remuneration of 4th series.

The Debentures will be registered to distribution on the primary and negotiation on the secondary market through (i) SDT - Securities Distribution Module and SND - National Debentures Module, respectively, both managed and operated by CETIP - Brazilian OTC Clearing House. The distribution and trades are settled and the Debentures are in electronic custody at CETIP.

The Offering aims exclusively qualified investors, according to items I and II, article 4, of CVM Instruction 476 and the public distribution registration in CVM is automatically exempt, pursuant to CVM Instruction 476.

Fitch attributed the rating AA- (bra) to the Offering, aligned with Amilpar’s corporate rating. This Offering is being coordinated by Banco BTG Pactual S.A. (Lead Coordinator), Banco Bradesco BBI S.A. and HSBC Corretora de Títulos e Valores Mobiliários S.A.

This material is informational only, according to the current legislation, and should not be considered as a material for the sale of Debentures.

To access the .pdf version of the Relevant Fact, click here.

Rio de Janeiro, September 14, 2010 - Amil Participações S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ e APAR ; Reuters: AMIL3 SA), the largest healthcare company in Brazil, informs that signed today through its subsidiary Amil Assistência Médica Internacional S.A. (“Amil”), a Purchase Agreement with the controlling shareholders of Excelsior Med Ltda. (“Saúde Excelsior”) for the acquisition and transference of the totality of the representative quotas of Saúde Excelsior’s capital.

The amount to be paid for the acquisition, subject to confirmation after the auditing process, is R$ 50 million and should be paid as follows: (i) R$ 2 million at the contract signature; (ii) 25% of the amount after ANS approval and (iii) the balance in 8 quarterly installments. The amounts described in items (ii) and (iii) will be adjusted for 85% of the variation of CDI (average interbank deposit rate in Brazil), since the contract signature until the effective payment. Amil will take over Excelsior’s liabilities and contingencies up to the limit of R$ 4 million.

Saúde Excelsior 2010 annualized revenues correspond to approximately R$ 180 million. The company has a membership of approximately 132 thousand members located in the Northeast region of Brazil, especially in the states of Pernambuco (89 thousand members), Rio Grande do Norte (11 thousand members), Alagoas (29 thousand members) and Paraíba (3 thousand members). Excelsior’s market share in Pernambuco is approximately 7%.

Before this acquisition, Amilpar’s market share in Pernambuco was more than 8% and with the recent acquisition of ASL in Natal already accounts with approximately 76 thousand members or 17% of market share in the state of Rio Grande do Norte.

The effectiveness of this acquisition is subject to the approval of the Brazilian Healthcare Agency - ANS (“Suspensive Condition”) and the Brazilian System of Competition Defense (CADE).

This deal represents one more step of the Company towards the growth and expansion in the Northeast region of Brazil.

To access the .pdf version of the Press Release, click here.

ASSEMBLÉIA GERAL EXTRAORDINÁRIA

Ficam os senhores acionistas da Amil Participações S.A. convocados para se reunir na Assembleia Geral Extraordinária a ser realizada na sede social da Companhia, localizada na Av. das Américas n.º 4.200, Bloco 3, Auditório, Barra da Tijuca, Cidade e Estado do Rio de Janeiro, no dia 16 de setembro de 2010, às 11h, para deliberar sobre a seguinte ordem do dia:

1. Deliberar sobre a proposta de redução do capital social da Companhia deliberada pelo Conselho de Administração da Companhia, em reunião realizada em 9 de agosto de 2010, de R$ 1.160.823.930,82 para R$ 1.156.593.345,14, com o respectivo cancelamento de 1.125.066 ações ordinárias nominativas, sem valor nominal, de emissão da Companhia, tendo em vista o exercício do direito de recesso por parte de acionistas minoritários da Medial Saúde S.A., no âmbito das operações (i) de incorporação de ações da Medial Saude S.A. pela Amil Assistência Médica Internacional S.A., e (i) de incorporação de ações da Amil Assistência Médica Internacional S.A. pela Companhia, na forma da assembleia geral da Companhia realizada em 30 de abril de 2010, com a consequente deliberação sobre a proposta de modificação do caput do artigo 5º do Estatuto Social da Companhia;

2. Deliberar sobre a proposta de modificação do estatuto social da Companhia, deliberada pelo Conselho de Administração da Companhia, em reunião realizada em 9 de agosto de 2010, para (i) modificar o quórum previsto no Parágrafo Dez do artigo 33, relativo à instalação da assembleia geral que tenha por objeto modificar as disposições estatutárias acerca da proteção à dispersão acionária; (ii) excluir o artigo 33 que trata da cláusula de proteção à dispersão acionária; e (iii) efetuar os ajustes de redação decorrentes da referida exclusão; e

3. Deliberar sobre a proposta de consolidação do estatuto social da Companhia para refletir (i) a modificação do estatuto social nos termos dos itens 1 e 2 acima, assim como (ii) as alterações estatutárias resultantes das deliberações tomadas pela assembleia geral extraordinária de 21.01.2008, relativas à periodicidade das reuniões do Conselho de Administração.

Informações Gerais: Os acionistas deverão apresentar à Companhia, com no mínimo 48 (quarenta e oito) horas de antecedência, além do documento de identidade e/ou atos societários pertinentes que comprovem a representação legal, conforme o caso: (i) comprovante expedido pela instituição escrituradora, no máximo, 5 (cinco) dias antes da datada realização da Assembleia Geral; (ii) o instrumento de mandato com reconhecimento da firma do outorgante; e/ou (iii) relativamente aos acionistas participantes da custódia fungível de ações nominativas, o extrato contendo a respectiva participação acionária, emitido pelo órgão competente.

Finalmente, em atenção às disposições legais e estatutárias pertinentes, encontram-se à disposição dos senhores acionistas, na sede social da Companhia, no endereço eletrônico da internet da Companhia (www.amilpar.com.br - Investidores), da BM&FBOVESPA S.A. - Bolsa de Valores, Mercadorias e Futuros (www.bmfbovespa.com.br) e da Comissão de Valores Mobiliários - CVM (www.cvm.gov.br) cópia dos documentos a serem discutidos nas referidas Assembleias, incluindo aqueles exigidos pela Instrução CVM 481/2009.

Rio de Janeiro, 30 de agosto de 2010

Edson de Godoy Bueno
Presidente do Conselho da Administração
Amil Participações S.A.
Fone: (21) 3805-1155
invest@amil.com.br
www.amilpar.com.br

Para acessar a versão em PDF, clique aqui.

Rio de Janeiro, August 10, 2010: Amilpar(Bovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR ; Reuters: AMIL3.SA), the largest healthcare company in Brazil, announced today its results for the second quarter of 2010 (2Q10). Given the acquisition of Medial’s control on December 1, 2009, for comparative purposes Amilpar’s results are presented excluding the effects of Medial‘s acquisition (pro-forma) and also with the consolidation of Medial’s results as of page 14 (in accordance with Brazilian Corporate Law). We are also presenting the results of Medial separately (as of page 11).

To access the PDF version click here.

AMIL PARTICIPAÇÕES S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR ‹GO›; Reuters: AMIL3 SA), the largest healthcare company in Brazil, informs that Fitch attributed to Amilpar, National Long-Term Rating “AA-(bra)”, with stable outlook. The obtaining of Amilpar’s corporate rating is aligned with the strategy of conversion of the Company’s current short term debt into long term.

Rio de Janeiro, August 3, 2010

Erwin Kleuser
Investor Relations Officer
Amil Participações S.A.
Phone: +55 (21) 3805-1155
invest@amil.com.br
www.amilpar.com

To access the PDF version click here.

Amil Participações S.A. (BM&FBovespa: AMIL3), the largest healthcare company in Brazil, announces its Earnings Release Schedule for the second quarter of 2010:

2Q10 Earnings Release
August 10, 2010 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Investor Relations:
Phone: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Website: www.amilpar.com.br/ir

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: www.amilpar.com.br/ir

Replay:
A conference call replay facility will be available from August 11 through August 17. To access the replay, dial the above mentioned numbers or access our website.

To download the file, click here.

AMIL PARTICIPAÇÕES S.A. (BM&FBOVESPA: AMIL3) (“Amilpar”), in accordance with CVM Instruction 358, of January 3, 2002, informs that CVM - Comissão de Valores Mobiliários (Brazilian Securities and Exchange Commission), approved on July 7, 2010 the request for the cancellation of the public company register of Medial Saúde S.A. (“Medial”).

Due to Medial’s register cancellation, Amilpar now is the only listed and publicly traded company in the group.

Rio de Janeiro, July 8, 2010

Erwin Kleuser
Investor Relations Officer
Amil Participações S.A.
Phone: +55 (21) 3805-1155
invest@amil.com.br
www.amilpar.com

To access the PDF version click here.

Amil Participações S.A (“Amilpar”), Amil Assistência Médica Internacional S.A. (“Amil Assistência”) and Medial Saúde S.A. (“Medial”) inform that the exchange ratios released in the Relevant Fact of June 7, 2010 (a) of 2.68 new Amil Assistência shares for each Medial share, in case of the incorporation of Medial shares by Amil Assistência, and (b) of 0.30 new Amilpar shares for each Amil Assistência share, in case of incorporation of Amil Assistência shares by Amilpar, are rounded figures, from 2.6790123456 and 0.3028037383, respectively, which will be used in the shares exchange ratios. This does not change the number of Amilpar shares to be issued and attributed to each one of the former Medial shareholders that did not exercise the withdrawal right due to the incorporation of shares involving the companies previously mentioned.

Rio de Janeiro, June 10, 2010.

Luiz Alves Filho
Diretor Presidente
Amil Assistência Médica Internacional S.A.
www.amil.com.br

For further information click here.

The management of Amil Participações S.A. ("Amilpar") and Medial Saúde S.A. ("Medial"), in accordance with article 157, paragraph 4, of Law 6,404/76 (Brazilian Corporate Law) and CVM Instruction nº 358/02, and in addition to the Relevant Facts released on April 13 and 30, 2010 and May 3, 2010, informs its shareholders and the market the following:

Incorporation of shares issued by Medial Saúde S.A.

1. On June 2, 2010, ended the deadline for holders of Medial common shares to manifest the right of withdrawal due to the incorporation of the totality of Medial shares by Amil Assistência Médica Internacional S.A. ("Amil Assistência"), matter of deliberation of the General Meetings of those companies held on April 29, 2010.

2. The refund amount due to the exercise of withdrawal right by Medial shareholders as consequence of the incorporation of the totality of Medial shares by Amil Assistência totaled R$ 24,270,557.50, corresponding to R$ 17.50 per share. The refund value will be paid to Medial shareholders on June 9, 2010.

3. Amil Assistência and Medial ratify the resolutions adopted at the General Meetings mentioned in item 1, and therefore will not exercise the power granted by article 137, paragraph 3, of Law 6,404/76.

4. Due to the incorporation of the totality of Medial shares by Amil Assistência, the last trading day of the Medial shares at the BM&FBOVESPA (trading code MEDI3) will be June 10, 2010.

5. As previously disclosed to the market, Medial shareholders that did not exercise the withdrawal right, will receive for each share issued by Medial, 2.68 common shares issued by Amil Assistência, a private company controlled by Amilpar, in substitution of their shares issued by Medial, with the consequences described in item 7.

6. Medial’s shareholders that due to the incorporation of shares remained with fractional share of Amil Assistência, will receive after the operation in substitution of such fraction, disregarding the quantity of shares and the respective fraction, 1 (one) share issued by Amil Assistência, as a donation from Amilpar, controlling shareholder of Amil Assistência.

Incorporation of shares issued by Amil Assistência Médica Internacional S.A.

7. Due to the incorporation of Amil Assistência shares by Amilpar, Medial shareholders who have not exercised the withdrawal in accordance with item 1 above could (a) exercise it in accordance with item 8 below, as shareholders of Amil Assistência or, (b) receive shares issued by Amilpar in substitution of the shares issued by Amil Assistência now being held by them.

8. On June 4, 2010 ended the deadline for holders of Amil Assistência and Amilpar common shares to manifest the exercise of withdrawal right due to the incorporation of the totality of Amil Assistência shares by Amilpar, matter of deliberation of the General Meetings of those companies held on April 30, 2010.

9. The withdrawal right due to the incorporation of the totality of Amil Assistência shares by Amilpar, was not exercised by any shareholder of Amil Assistência or Amilpar.

10. Amil Assistência and Amilpar ratify the resolutions adopted at the General Meetings mentioned above, and therefore will not exercise the power granted by article 137, paragraph 3, of Law 6,404/76.

11. As previously disclosed to the market, Amil Assistência shareholders that did not exercise the withdrawal right due to the incorporation of shares of such company by Amilpar will receive for each share issued by Amil Assistência, 0.30 common share issued by Amilpar, in substitution of their shares issued by Amil Assistência.

12. Shareholders that due to the incorporation of shares issued by Amil Assistência remained with fractional share issued by Amilpar, will receive after the operation in substitution of such fraction, disregarding the quantity of shares and the respective fraction, 1 (one) share issued by Amilpar, as a donation from JPLSPE Empreendimentos e Participações S.A., controlling shareholder of Amilpar.

13. Amilpar shares related to incorporations mentioned above will be credited on June 16, 2010.

For additional information please contact Amilpar Investor Relations Department at the phones and emails below.

Rio de Janeiro, June 7, 2010.

To download the file, click here.

Rio de Janeiro, May 11, 2010: Amilpar (BM&FBOVESPA: AMIL3; Bloomberg: AMIL3 BZ and APAR <GO>; Reuters: AMIL3.SA), the largest Healthcare company in Brazil, announced today its results for the first quarter of 2010 (1Q10). Given the acquisition of Medial’s control on December 1, 2009, for comparative purposes Amilpar’s results are presented excluding the effects of Medial’s acquisition (pro-forma) and also with the consolidation of Medial’s results since December 2009 (in accordance with Brazilian Corporate Law). Additionaly, this report is presenting the results of Medial separately (as of page 11).

To download the file, click here.

Amil Participações S.A (BM&FBovespa: AMIL3) (“Amilpar” or “Company”), in accordance with article 157, paragraph 4, of Law 6,404/76 (Brazilian Corporate Law) and CVM Instructions nº 358/02 and 319/99, and in addition to the Relevant Facts released on November 19, 2009, April 5, 2010 and April 13, 2010, informs its shareholders and the market that on April 30, 2010 the Extraordinary General Shareholders Meetings of the Company and its subsidiary Amil Assistência Médica Internacional S.A. (“Amil Assistência”) were held, being approved in both meetings, based on article 252 of the Brazilian Corporate Law, the incorporation, by the Company, of the totality of the shares issued by Amil Assistência, excluding those currently owned by the Company.

The incorporation of Amil Assistência shares by Amilpar constitutes the second and last step of the corporate restructuring released in the relevant fact of April 13, 2010, turning Medial Saúde S.A. (“Medial”) into an integral subsidiary of Amil Assistência and the latter into an integral subsidiary of Amilpar. As consequence, the shareholding basis of Medial and Amil Assistência, composed by the shareholders that do not exercise the withdrawal right due to the approval of the above mentioned corporate restructuring, will be transferred to Amilpar.

Amilpar’s new capital stock

Due to the incorporation of the shares issued by Amil Assistência, Amilpar’s new capital stock was raised in R$ 5,122,348.82, moving from R$ 1,155,701,582.00 to R$ 1,160,823,930.82. As consequence, were issued 1,362,218 new common shares with no par value, at the issuance price of R$ 3.7603 per share, which were (i) subscribed by the Management of Amil Assistência on behalf of its shareholders, (ii) and attributed to non-controlling shareholders of Amil Assistência, in the proportion of their respective participations in Amil Assistência capital stock, according to the exchange ratio mentioned above.

To download the file, click here.

Amil Participações S.A. (BM&FBovespa: AMIL3), the largest health care company in Brazil, announces its Earnings Release Schedule for the first quarter of 2010:

1Q10 Earnings Release
May 11, 2010 (After market closing)

Participants are requested to connect 10 minutes prior to the time set for the conference calls.

Investor Relations:
Phone: +55 (21) 3805-1155
E-mail: invest@amil.com.br
Website: www.amilpar.com.br/ir

Webcast:
The Conference Call audio and slides presentation will be live broadcasted on the Internet at the following link: www.amilpar.com.br/ir

Replay:
A conference call replay facility will be available from May 12 through May 18. To access the replay, dial the above mentioned numbers or access our website.

To download the file, click here.